DocuSign Envelope ID: 07968481-AA88-48A0-8896-22F5618C954B

May 18, 2020

By E-Mail

Mr. Glenn J. Perry
604 Wake Forest Ln.
The Villages, FL 32162
E-Mail: gjperry@gmail.com

Re: Agreement to Serve as a Member of Askeladden L.L.C.'s Patent Challenge Committee

Dear Mr. Perry:

We are very pleased that you have agreed to serve as a member of the Patent Challenge Committee of Askeladden L.L.C. ("Askeladden"). This letter agreement ("Letter Agreement") describes the terms and conditions governing the relationship between you and Askeladden pursuant to which you will serve as a member of the Patent Challenge Committee in accordance with the provisions of the February 1, 2018, Amended and Restated Limited Liability Company Agreement of Askeladden L.L.C. and the accompanying Patent Challenge Guidelines attached as Exhibit A thereto (collectively, and as they may be amended from time to time, the "Amended Askeladden L.L.C. Agreement"). A copy of the Amended Askeladden L.L.C. Agreement is attached hereto as Exhibit A.

1. Undertaking to Be Bound by the Amended Askeladden L.L.C. Agreement and Patent Challenge Guidelines: You acknowledge that you have received, read and understand all of the provisions of the Amended Askeladden L.L.C. Agreement, and you agree to: (i) comply with the provisions of the Amended Askeladden L.L.C. Agreement that apply to you as a member of the Patent Challenge Committee, including Section 11 thereof; and (ii) consider the provisions of the Patent Challenge Guidelines in connection with the performance of your duties as a member of Askeladden's Patent Challenge Committee. Askeladden acknowledges and agrees that you are a third-party beneficiary of the exculpation and indemnification provisions set forth in Section 24 of the Amended Askeladden L.L.C. Agreement.

2. No Conflict of Interest: Askeladden understands and you acknowledge that you are available to work as a member of the Patent Challenge Committee for up to ten (10) hours per month, or up to twenty (20) hours per month in the event that you serve as lead member of the Patent Challenge Committee as provided in the Amended Askeladden L.L.C. Agreement. Askeladden further understands and you acknowledge that serving as a member of the Patent Challenge Committee will not to your knowledge create a conflict of interest in connection with your relationship with any third party or with respect to any work that you have undertaken with or for others. In addition, you represent and warrant that to your knowledge, you do not have any conflict of interest with respect to your service as a member of Askeladden's Patent Challenge Committee. If any conflict or potential conflict of interest arises

in connection with a matter during your term as a member of the Patent Challenge Committee, you agree to immediately identify that conflict and recuse yourself from all deliberations and any other consideration of that matter by the Patent Challenge Committee. Askeladden and you acknowledge and agree that as a member of the Patent Challenge Committee you will not be providing legal services or advice to Askeladden, and that no attorney-client relationship will exist between either you as attorney and Askeladden as client, by virtue of your service as a member of the Patent Challenge Committee. So long as you are a member of the Patent Challenge Committee, Askeladden agrees to make commercially reasonable efforts to obtain and maintain in effect liability insurance coverage in an amount that provides for a defense and a reasonable level of coverage for claims and liabilities relating to your service on the Committee, and to advise you promptly of any termination or material reduction of any such coverage.

3. Independent Contractor: You acknowledge and confirm that in your capacity as a member of the Patent Challenge Committee, you will be acting as an independent contractor of Askeladden, and that nothing contained herein shall be construed as or operate to create an agency, partnership, joint venture, employment or other form of joint enterprise between you and Askeladden. You shall not subcontract any portion of your work under this Letter Agreement.

4. Term: You agree to serve as a member of the Patent Challenge Committee for an initial term of two (2) years, beginning on May 20, 2020, and you agree that your continued service and appointment for any subsequent terms shall be governed by Section 11 of the Amended Askeladden L.L.C. Agreement. Within forty-five (45) days after the conclusion of your service as a member of the Patent Challenge Committee, unless otherwise agreed to by Askeladden and you, all Confidential Information (as defined below) in your possession, custody or control shall be returned to Askeladden. Askeladden reserves the right to seek the immediate return of all Confidential Information during and after your tenure as a member of Askeladden's Patent Challenge Committee. This Letter Agreement shall terminate upon the termination of your service as a member of the Patent Challenge Committee; provided, however, that the rights and obligations set forth in this Section 4 and in Sections 7 through 9 of this Letter Agreement shall survive the expiration or termination of this Letter Agreement.

5. Compensation: In consideration for your services as a member of Askeladden's Patent Challenge Committee, Askeladden agrees to compensate you at the rate of [redacted] per calendar quarter, or at the rate of [redacted] per calendar quarter during periods in which you may serve as the lead member of the Patent Challenge Committee. In addition, Askeladden will reimburse you for reasonable out-of-pocket expenses that you incur in connection with the performance of your services as a member of the Patent Challenge Committee. You agree to provide Askeladden with quarterly invoices of time spent and monthly invoices for reasonable expenses incurred in connection with your work as a member of the Patent Challenge Committee. Askeladden will pay and reimburse you within thirty (30) days of receipt of your invoices. Invoices should be addressed to the General Counsel of Askeladden as follows:

Sean M. Reilly
General Counsel

Askeladden L.L.C.
1114 Avenue of the Americas, 17th Floor
New York, NY 10036

6. Public Relations: Askeladden shall have the right at its discretion to release information or to publish material that relates to your participation as a member of the Patent Challenge Committee. As part of your services as a member of Askeladden's Patent Challenge Committee, you agree to participate as reasonably requested in Askeladden's public relations efforts related to its patent challenges (e.g. meet with reporters, provide quotes for press releases, etc.).

7. Confidentiality: "Confidential Information" shall mean information that is expressly and explicitly designated confidential and/or privileged, the disclosure of which may be materially damaging to Askeladden. You agree that all Confidential Information from time to time known, disclosed, divulged, communicated, furnished or otherwise made available to you by Askeladden shall be used solely for the purpose of enabling you to perform and discharge your duties and responsibilities hereunder. Except as required by law, subpoena or other judicial process, as specifically required to perform and discharge your duties and responsibilities hereunder, or as specifically directed by Askeladden, you agree that you will not at any time disclose any Confidential Information to any person for any other purpose, and that upon the request of Askeladden, you will return to Askeladden all Confidential Information in your possession, custody or control.

8. Limitation of Liability: EXCEPT AS PROVIDED BELOW, IN NO EVENT SHALL EITHER PARTY BE LIABLE FOR ANY INDIRECT, INCIDENTAL, SPECIAL, EXEMPLARY, PUNITIVE OR CONSEQUENTIAL DAMAGES OF ANY KIND, INCLUDING LOST PROFITS, ARISING OUT OF THIS LETTER AGREEMENT, HOWEVER CAUSED, AND ON ANY THEORY OF LIABILITY, EVEN IF THE PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. This section shall not apply to or limit: (a) any liability or damages that might arise in connection with any willful or intentional breach by you of the confidentiality obligations set forth herein; or (b) any liability or damages arising from or in connection with fraud, willful misconduct or gross negligence of either party.

9. Miscellaneous: This Letter Agreement shall be governed by and construed in accordance with the law of the State of New York applicable to agreements made and to be performed wholly within such state. Any suit, action or other proceeding arising in connection with this Letter Agreement (each a "Proceeding") shall be brought in the courts of the State of New York or of the United States of America located in the Borough of Manhattan in the State of New York, and the parties hereby irrevocably submit to the jurisdiction of each such court. The parties further irrevocably waive any objection they may have now or hereafter to the laying of venue of any Proceeding brought in any such court, and hereby further irrevocably waive any claim that any Proceeding brought in any such court has been brought in an inconvenient forum. Neither party may assign this Letter Agreement or any of its rights or obligations hereunder. You shall not use Askeladden's name, trademark or logos in any manner without the prior written approval of Askeladden. This Letter Agreement constitutes the entire agreement

between the parties with respect to the subject matter hereof. This Letter Agreement supersedes and replaces all prior oral or written agreements between the parties. This Letter Agreement may be amended only in a writing signed by both parties. Forbearance or neglect on the part of either party to insist upon strict compliance with the terms of this Letter Agreement shall not be construed as or constitute a waiver thereof. If any provision of this Letter Agreement is determined to be illegal, invalid or unenforceable by a court of competent jurisdiction, the remainder of this Letter Agreement shall remain in full force and effect. Section headings are for the convenience of the parties only and shall not be used to alter or amend any provision of this Letter Agreement. As used herein, "include," "includes," and "including" mean include, includes or including (as the case may be) without limitation. This Letter Agreement may be executed in separate counterparts, each of which will be deemed an original, and all of which will be deemed one and the same instrument.

If the terms recited above are consistent with your understanding of our agreement and meet with your approval, please sign and date this Letter Agreement before returning it to me. This Letter Agreement shall be neither binding nor effective as to either you or Askeladden, and your term as a member of the Patent Challenge Committee shall not become effective, until such time as, following Askeladden's receipt of a copy of this Letter Agreement signed by you, this Letter Agreement has been duly approved and/or accepted (as the case may be as noted below) by each of James Howard, Sean Reilly and Rob Hunter.

Very truly yours,

Sean M. Reilly
General Counsel
Askeladden L.L.C.

ACKNOWLEDGED, ACCEPTED AND AGREED TO

DocuSigned by:

By: Glenn Perry
0BA5CDB039874F7...

Glenn J. Perry

Date: 5/20/2020 | 2:35 PM PDT

Askeladden L.L.C.

Approved by: DocuSigned by: Jim Howard 7D4FA45EC6CB4DE...
Name: James Howard

Approved by: DocuSigned by: Sean Reilly 67C9829596ED4F8...
Name: Sean Reilly

Accepted by: DocuSigned by: 5517787CA0FD4F7...
Name: Rob Hunter

DocuSign Envelope ID: 07968481-AA88-48A0-8896-22F5618C954B

Exhibit A

DocuSign Envelope ID: 07968481-AA88-48A0-8896-22F5618C954B

CONFIDENTIAL

AMENDED AND RESTATED LIMITED LIABILITY COMPANY AGREEMENT OF ASKELADDEN L.L.C.

This Amended and Restated Limited Liability Company Agreement (this "**Agreement**") of Askeladden L.L.C (the "**Company**"), a single member limited liability company, is entered into by The Clearing House Payments Company L.L.C. as the sole member (the "**Sole Member**") and shall be effective as of February 1, 2018.

The Sole Member formed the Company on June 17, 2014 as a limited liability company pursuant to the Delaware Limited Liability Company Act, 6 Del. C § 18-101, et seq., as amended from time to time (the "**Act**").

The Sole Member entered into a limited liability company agreement of the Company effective as of July 9, 2014. The Sole Member entered into an amended and restated limited liability company agreement of the Company effective as of March 1, 2016 (the "2016 Amended and Restated Agreement").

The Sole Member desires to amend and restate the 2016 Amended and Restated Agreement as follows:

1. Name. The name of the limited liability company is Askeladden L.L.C.

2. Duration. The duration of the Company shall be perpetual, and the Company shall dissolve only as provided in Section 16.

3. Purpose. The Company is formed for the object and purpose of, and the nature of the business to be conducted and promoted by the Company is, engaging in any lawful act or activity for which limited liability companies may be formed under the Act and engaging in any and all activities necessary or incidental to the foregoing.

4. Principal Business Office. The principal business office of the Company shall be located at 1114 Avenue of the Americas, New York, NY 10036, or at such other location as may hereafter be determined by the Executive Committee (as defined below).

5. Registered Office. The address of the registered office of the Company within the State of Delaware is Corporation Trust Center, 1209 Orange Street, County of New Castle, Wilmington, Delaware 19801.

6. Registered Agent. The name of the registered agent of the Company for service of process on the Company in the State of Delaware is The Corporation Trust Company.

7. Sole Member. The Sole Member is The Clearing House Payments Company L.L.C.

8. Authorized Persons. It is hereby ratified and confirmed that John Sorensen was designated as an authorized person, within the meaning of the Act, to execute, deliver and file the certificate of formation of the Company. Each of the Sole Member, any

individual designated by the Executive Committee (as defined below), and any Officer (as defined below) of the Company (as may from time to time be designated in accordance with this Agreement) is hereby designated as an authorized person within the meaning of the Act to execute, deliver and file any amendment and/or restatement of the certificate of formation of the Company and any other certificates (and any amendments and/or restatements thereof) necessary for the Company to qualify to do business in a jurisdiction in which the Company may wish to conduct business.

9. Executive Committee.

a) Except as provided for in Sections 10 and 11, the Executive Committee as described in this Section 9 shall be solely responsible, among other things, for: (i) managing the business and affairs of the Company, including in connection with the Patent Quality Initiative; (ii) selecting both the sources of funding for the Company and the uses of funds of the Company; and (iii) selecting service providers for the Company, which may be the Sole Member or any third party. The Executive Committee shall be the Company's "manager" within the meaning of the Act. The Company will have no employees. The services provided by personnel of the Sole Member who serve as members of the Executive Committee of the Company, as Officers (as defined below) of the Company, or who provide ancillary business services to or for the Company (e.g., accounting services), will be provided pursuant to a services agreement between the Sole Member and the Company. The members of the Executive Committee shall be designated and may be removed by the Sole Member at its discretion, and each such member of the Executive Committee shall serve until removed by the Sole Member or until his or her earlier resignation as provided herein. Any member of the Executive Committee may resign at any time by written notice to the Executive Committee. A resignation shall take effect at the time specified in the notice (or, in the absence of a specified time, the time of receipt). Unless otherwise stated in a notice of resignation, no acceptance of the resignation shall be necessary to make it effective.

b) The Executive Committee shall consist of at least three (3) members selected by the Sole Member from among the current officers of the Sole Member.

c) When the Executive Committee consists of an even number of members, one-half of the members of the Executive Committee at any time in office shall constitute a quorum of the Executive Committee. When the Executive Committee consists of an odd number of members, a simple majority of the members of the Executive Committee at any time in office shall constitute a quorum of the Executive Committee. Each member of the Executive Committee shall have one vote on all matters presented to the Executive Committee for a vote. Every act or decision done or made by a majority of the members of the Executive Committee present at a meeting of the Executive Committee duly held at which a quorum is present shall be regarded as the act of the Executive Committee, including the formation, execution and fulfillment of contracts, and shall be executed by an Executive Committee member or an Officer (as described below) at the direction of the Executive Committee. No individual member of the Executive Committee, acting as such, shall have any authority to bind or act for, or assume any obligation or responsibility on behalf of the Company. Meetings of the Executive Committee may be held at any time and place designated in a call by one or more members of the Executive Committee. Any action required or permitted to be taken at any meeting of the Executive

DocuSign Envelope ID: 07968481-AA88-48A0-8896-22F5618C954B

Committee may be taken without a meeting by written consent, if all members of the Executive Committee consent to the action in writing or by electronic transmission and the written consents or electronic transmissions are filed with the minutes of proceedings of the Executive Committee.

10. **Major Decisions.** Notwithstanding the authority delegated to the Executive Committee under Section 9, prior written approval of the Sole Member shall be required in order to:

a) Issue any equity, voting or other interest in the Company to any Person or admit any additional members of the Company;

b) Merge or consolidate the Company with or into another Person (or take any action that has substantially the same effect);

c) Sell, dispose of or otherwise transfer all or a substantial part of the Company's assets or operations;

d) Take any action in furtherance of, or indicate consent to, approval of or acquiescence in, any Bankruptcy (as defined below) of the Company;

e) Dissolve, liquidate or wind-up the Company; or

f) Waive this Section 10.

As used herein, the term "Bankruptcy" means, with respect to any entity: (i) the entry of an Order for Relief under Title 11 of the United States Code; (ii) the admission by such entity of its inability to pay its debts as they mature; (iii) the making by it of an assignment for the benefit of creditors; (iv) the filing by it of a petition in bankruptcy or a petition for relief under Title 11 of the United States Code or any other applicable federal or state bankruptcy or insolvency law; (v) the expiration of sixty days after the filing of an involuntary petition under Title 11 of the United States Code, an application for the appointment of a receiver for the assets of such entity, or an involuntary petition seeking liquidation, reorganization, arrangement or readjustment of its debts under any other federal or state insolvency law, provided that the same shall not have been vacated, set aside or stayed within such sixty-day period; (vi) the appointment of a conservator or receiver in respect of it under the Federal Deposit Insurance Act or other applicable law; (vii) the imposition of a judicial or statutory lien on all or a substantial part of its assets unless such lien is discharged or vacated or the enforcement thereof stayed within sixty days after its effective date; or (viii) any comparable or similar proceeding under the laws of any country other than the United States.

As used herein, the term "Person" shall mean any natural person, partnership (whether general or limited), limited liability company, trust, estate, association, corporation, custodian, nominee or any other individual or entity in its own or any representative capacity.

11. **Patent Challenge Committee.**

a) Subject to Section 11(b) hereof, the Company shall have a Patent Challenge Committee, the purpose of which shall be to independently implement, manage and conduct that aspect of the Company's Patent Quality Initiative directed to challenging the validity of low-quality patents as specified in the Patent Challenge Guidelines attached hereto as Exhibit A (the "**Patent Challenge Guidelines**"), including, without limitation, by identifying appropriate patents for challenge, directing the filing of petitions to the PTAB challenging the validity of patents selected by the Patent Challenge Committee, and overseeing the prosecution, conduct and management of proceedings initiated by the PTAB to review the validity of challenged patents (the "**Purpose**"). The Patent Challenge Committee will undertake its responsibilities in connection with the Purpose by, without limitation, challenging the validity of selected patents utilizing Inter Partes Review ("**IPR**") and Post-Grant Review ("**PGR**") proceedings as appropriate before the Patent Trial and Appeal Board ("**PTAB**").

b) The Patent Challenge Committee shall terminate in the event of: (i) a dissolution, liquidation or winding-up of the Company; or (ii) a determination of the Executive Committee to cease pursuit of the Purpose effective only upon completion of all IPRs and/or PGRs pending at the time of such determination.

c) The Patent Challenge Committee shall be solely responsible for carrying out the Purpose and shall operate independently of the Executive Committee, the Sole Member and any other Person that is affiliated with or otherwise related to the Sole Member of the Company, provided, however, that the Patent Challenge Committee shall consider (but shall not be bound by) the principles set forth in the Patent Challenge Guidelines, and provided further that the Executive Committee may appoint, in its discretion, a Person or Persons affiliated with the Sole Member to assist and support the activities of the Patent Challenge Committee. Such a Person(s) shall provide such assistance and support at the discretion of the Patent Challenge Committee, but shall have no authority to direct, bind or otherwise control the activities of the Patent Challenge Committee.

d) The Executive Committee shall select natural persons to serve as members of the Patent Challenge Committee, which shall consist of three (3) independent members who shall not be a director, officer, employee, representative, agent or otherwise related to or under the control or direction of the Company, the Sole Member or any other Person that is affiliated with or otherwise related to the Company or the Sole Member. The three (3) members of the Patent Challenge Committee shall be chosen by the Executive Committee based on their qualifications to carry out the Purpose of the Patent Challenge Committee, and shall have training, experience or expertise in one or more of the fields of intellectual property law, patent litigation, Patent Office practice and procedure or technology related to financial services. The members of the Patent Challenge Committee may select from among themselves a lead Patent Challenge Committee member (the "lead member"), and authorize such lead member to undertake such tasks as they determine to be appropriate, including, without limitation, supervision of outside counsel and Persons who may be designated by the Executive Committee to assist and support the Patent Challenge Committee, and overseeing the prosecution, conduct and management of IPRs and PGRs. The Patent Challenge Committee may change the lead member at any time in its discretion.

DocuSign Envelope ID: 07968481-AA88-48A0-8896-22F5618C954B

c) One (1) of the three (3) members of the Patent Challenge Committee shall serve for an initial term of one (1) year and the other two (2) members shall serve on the Patent Challenge Committee for an initial term of two years. Following those initial terms, any successive term of each member of the Patent Challenge Committee shall be two (2) years. The service of a member of the Patent Challenge Committee shall not be terminated except by a vote of the majority of the Executive Committee for cause based on: (i) any act or failure to act in compliance with the provisions of or satisfy the duties and responsibilities of a member of the Patent Committee Challenge set forth in this Section 11; (ii) the fraud, dishonesty, theft, bad faith or other willful misconduct of an independent member; or (iii) the repeated failure of such member (after reasonable notice of such failure and a reasonable opportunity to cure such failure) to substantially perform his or her duties as a member of the Patent Challenge Committee. Any of the three (3) members of the Patent Challenge Committee may resign at any time by written notice to the Executive Committee, and such resignation shall take effect at the time specified in the notice (or, in the absence of a specified time, the time of receipt). Unless otherwise stated in a notice of resignation, no acceptance of the resignation shall be necessary to make it effective. Upon the resignation or removal for cause of any of the three (3) members of the Patent Challenge Committee, the Executive Committee shall promptly appoint a replacement in accordance with the provisions of this Section 11. The terms of each member of the Patent Challenge Committee shall terminate if the Patent Challenge Committee is terminated pursuant to Section 11(b) hereof.

f) Each of the three (3) members of the Patent Challenge Committee shall be compensated for their services pursuant to an agreement with the Company at a rate consistent with their ordinary fees or rates for like services.

g) The Executive Committee shall establish an annual budget for the Patent Challenge Committee's activities, and an annual target range for the number of patent challenges by the Patent Challenge Committee. The Patent Challenge Committee shall have sole discretion regarding the use of the funds included in its annual budget, and sole discretion and responsibility for selecting and engaging any service providers, including, but not limited to, outside legal counsel, experts and prior art search firms, in connection with its activities. The Patent Challenge Committee may form and execute contracts on behalf of the Company pertaining to the Patent Challenge Committee's activities. Such contracts may be executed by a Patent Challenge Committee member at the direction of the Patent Challenge Committee or, if the contract provides for the payment of no more than $25,000, by the lead member of the Patent Challenge Committee pursuant to the authority delegated to the lead member by the Patent Challenge Committee. Other than as expressly provided herein, no member of the Patent Challenge Committee shall have any authority to bind or act for, or assume any obligation or responsibility on behalf of the Company.

h) Each of the three (3) members of the Patent Challenge Committee shall have one vote on all matters presented for a vote, and the approval of a majority of the members of the Patent Challenge Committee shall be required to approve any matter presented for a vote. The Patent Challenge Committee may act with or without a meeting, but any action taken with a meeting shall be recorded in minutes of that meeting and any action taken without a meeting shall be taken and recorded by a vote by written or electronic transmission.

DocuSign Envelope ID: 07968481-AA88-48A0-8896-22F5618C954B

i) Each member of the Patent Challenge Committee, including with the assistance and support of any Person affiliated with the Sole Member designated by the Executive Committee to provide such assistance and support, may identify for the Patent Challenge Committee's consideration a patent or patents that could be challenged by the Patent Challenge Committee in furtherance of the Purpose. The Patent Challenge Committee shall hold a vote to determine whether to challenge the validity of a patent.

j) The Patent Challenge Committee shall hold a vote in connection with decisions regarding the ultimate disposition of IPR and PGR proceedings before the PTAB, including, without limitation, decisions to settle with the respondent and terminate a proceeding.

k) Any member of the Patent Challenge Committee may object to a decision by vote of the Patent Challenge Committee on the grounds that the decision contravenes the Purpose, the provisions of this Section 11, and/or the Patent Challenge Guidelines, or cannot be implemented with funds available to the Patent Challenge Committee. If such an objection is made regarding a decision by the Patent Challenge Committee and the Patent Challenge Committee is unable to resolve it, the Patent Challenge Committee shall not implement or execute its decision unless all three (3) members of the Patent Challenge Committee vote to overrule the objection.

l) Other than the assistance and support provided to the Patent Challenge Committee by the Person(s) affiliated with the Sole Member designated by the Executive Committee to provide such assistance and support, and as requested by the Patent Challenge Committee, the Executive Committee, the Sole Member, and any Persons that are affiliated with or otherwise related to the Sole Member shall not provide, and the Patent Challenge Committee shall not accept, any request or suggestion that the Patent Challenge Committee institute review of any specific patent (or the patents of a particular patent owner) or any direction or suggestion with respect to carrying out the Purpose from the Executive Committee, the Sole Member or any other Person that is affiliated with or otherwise related to the Sole Member.

m) The Sole Member and any Persons that are affiliated with or otherwise related to the Sole Member will not make payments to the Company to fund any of the specific patent challenge activities of the Company (i.e., Persons affiliated with or otherwise related to the Sole Member may make initial payments and successive rounds of payments as necessary to capitalize the Company, but will not compensate the Company for challenging any certain or specific patents).

n) The Patent Challenge Committee should avoid advancing arguments that would tend to support a finding that the Company is a proxy for the Sole Member or any other Person that is affiliated with or otherwise related to the Sole Member, or that the Company and the Sole Member and any other Person that is affiliated with or otherwise related to the Sole Member are in privity when responding to contentions by patent owners that the Company lacks standing to appeal a PTAB decision that the claims of a challenged patent are valid. The Patent Challenge Committee should take special care to avoid such arguments in any attempt it makes to establish that the Company has a personal stake in the outcome and has suffered an "injury in fact."

DocuSign Envelope ID: 07968481-AA88-48A0-8896-22F5618C954B

12. Certain Prohibited Actions. The Company shall not directly or indirectly carry on any activity that would prohibit a national bank or a member bank of the Federal Reserve System from being a member of the Sole Member.

13. Officers. The Executive Committee may select natural persons to be designated as officers of the Company (the "**Officers**"), with such titles as the Executive Committee shall determine. Any number of offices may be held by the same person. The Officers shall hold office until their successors are chosen and qualified. Any Officer may resign at any time upon written notice to the Executive Committee. Any Officer elected or appointed by the Executive Committee may be removed at any time by the Executive Committee. Any vacancy occurring in any office of the Company may be filled by the Executive Committee. The Officers shall have such powers and duties in the management of the Company as may be delegated to them in this Agreement or by the Executive Committee, except that in any event each Officer shall exercise such powers and perform such duties as may be required by law. The Officers, or any one of them, shall have the authority to execute and deliver such documents, instruments and certificates in such forms and with such terms as the Executive Committee may approve, such Officer's execution thereof to be conclusive evidence of such approval, and to take such other actions as the Officers, or any one of them, may deem necessary or appropriate.

14. Officers as Agents. The Officers, to the extent of their powers set forth in this Agreement or by the decision of the Executive Committee, are agents of the Company for the purpose of the Company's business, and the actions of the Officers taken in accordance with such powers shall bind the Company.

15. Reliance by Third Parties. Any Person dealing with the Company or any Officer may rely upon a certificate signed by an Officer as to:

a) the identity of the Sole Member or any Officer;

b) the existence or non-existence of any fact or facts which constitute a condition precedent to acts by an Officer or in any other manner germane to the affairs of the Company;

c) the Persons who are authorized to execute and deliver any instrument or document of or on behalf of the Company; or

d) any act or failure to act by the Company or as to any other matter whatsoever involving the Company or the Sole Member.

16. Dissolution. The Company shall dissolve, and its affairs shall be wound up upon the first to occur of the following: (a) the written consent of the Sole Member, provided that the Sole Member gives the Executive Committee three months' notice of its decision to dissolve the Company, if practicable; or (b) the entry of a decree of judicial dissolution under § 18-802 of the Act.

17. Capital Contributions. The Sole Member is not required to make any capital contribution to the Company.

DocuSign Envelope ID: 07968481-AA88-48A0-8896-22F5618C954B

18. Additional Contributions. The Sole Member is not required to make any additional capital contribution to the Company.

19. Allocation of Profits and Losses. The Company's profits and losses shall be allocated to the Sole Member.

20. Distributions. Distributions shall be made to the Sole Member at the times and in the aggregate amounts determined by the Executive Committee.

21. Tax Matters. The Company shall be disregarded as an entity separate from its owner for U.S. federal and state income tax purposes and all items of income, gains, loss, or deduction of the Company shall be considered items of income, gain, loss or deduction of the Sole Member.

22. Resignation. The Sole Member may not resign as a member of the Company.

23. Liability. Neither the Sole Member, nor any member of the Executive Committee, member of the Patent Challenge Committee, any Person designated by the Executive Committee to assist and support the activities of the Patent Challenge Committee, or any Officer of the Company shall have any liability under this Agreement, the certificate of formation of the Company or the Act except as expressly provided herein or as required by the Act. Except as required by applicable law, the debts, obligations and liabilities of the Company, whether arising in contract, tort or otherwise (including those arising as member, owner or shareholder of any other person and those related to any expense of the Company), shall be solely the debts, obligations and liabilities of the Company, and neither the Sole Member, nor any member of the Executive Committee, member of the Patent Challenge Committee, any Person designated by the Executive Committee to assist and support the Patent Challenge Committee or any Officer of the Company shall be personally obligated for any such debt, obligation or liability of the Company by reason of acting in such capacity.

24. Exculpation and Indemnification. Neither the Sole Member, nor any member of the Executive Committee, member of the Patent Challenge Committee, any Person designated by the Executive Committee to assist and support the Patent Challenge Committee or any Officer of the Company, nor any successor, assign, heir or legal representative of any of the foregoing (each a "**Covered Person**"), shall be liable to the Company or any other Person who has an interest in the Company for: (i) any loss, damage or claim incurred by reason of any act or omission performed or omitted by such Covered Person in good faith on behalf of the Company and in a manner reasonably believed to be within the scope of the authority conferred on such Covered Person by this Agreement, except that a Covered Person shall be liable for any such loss, damage or claim (including costs of investigation and attorneys' fees and expenses) (**"Damages"**) incurred by reason of such Covered Person's bad faith, fraud or willful misconduct; (ii) such Covered Person's performance of, or failure to perform, any act in reasonable reliance on the advice of legal counsel to the Company; or (iii) the negligence, dishonesty or bad faith of any agent, consultant or broker of the Company selected, engaged or retained in good faith. To the fullest extent permitted by applicable law, the Company shall defend, indemnify and hold harmless each Covered Person against any Damages incurred by

DocuSign Envelope ID: 07968481-AA88-48A0-8896-22F5618C954B

such Covered Person in each case actually and reasonably incurred by such Covered Person or on its behalf, by reason of any act or omission performed or omitted by such Covered Person in good faith on behalf of the Company and in a manner reasonably believed to be within the scope of the authority conferred on such Covered Person by this Agreement, except that no Covered Person shall be entitled to be indemnified in respect of any Damages incurred by such Covered Person by reason of such Covered Person's bad faith, fraud or willful misconduct with respect to such acts or omissions, *provided, however*, that any indemnity under this Section 24 shall be provided out of and to the extent of Company assets only, and no Covered Person shall have personal liability on account thereof. No amendments to this Section 24 shall impair the rights of any Covered Person arising at any time with respect to events occurring prior to such amendment. Nothing in Section 23 or Section 24 shall limit or affect any other right of any person to indemnification or reimbursement of Damages under this Agreement or any other agreement (including any insurance policy), any constituent document of any other person, any statute, rule or regulation or otherwise.

25. Amendment. This Agreement may be amended only with the prior written consent of the Sole Member, provided, no amendment to this Agreement shall cause any IPRs or PGRs pending at the time of the amendment to be terminated or remove the Patent Challenge Committee's control of such proceedings.

26. Governing Law. This Agreement shall be governed by, and construed under, the laws of the State of Delaware, all rights and remedies being governed by said laws.

27. Severability. The invalidity and unenforceability of any particular provision of this Agreement in any jurisdiction shall not affect the other provisions hereof, and this Agreement shall be construed in all respects as if such invalid or unenforceable provisions were omitted.

[*Remainder of page left intentionally blank.*]

DocuSign Envelope ID: 07968481-AA88-48A0-8896-22F5618C954B

CONFIDENTIAL

IN WITNESS WHEREOF, the undersigned, intending to be legally bound hereby, has duly executed this Amended and Restated Limited Liability Company Agreement.

THE CLEARING HOUSE PAYMENTS COMPANY L.L.C.

By: _____

Name: **James Aramanda**

Title: President and Chief Executive Officer

DocuSign Envelope ID: 07968481-AA88-48A0-8896-22F5618C954B

CONFIDENTIAL

EXHIBIT A

PATENT CHALLENGE GUIDELINES

DocuSign Envelope ID: 07968481-AA88-48A0-8896-22F5618C954B

I. Overview of Patent Quality Initiative

The Company's Patent Quality Initiative seeks to improve the quality of patents that affect the financial services industry, without limitation, by: (1) briefing examiners at the U.S. Patent and Trademark Office (the "PTO") about the technology and systems employed in the past and present by members of the financial services industry; (2) filing of amicus briefs in appropriate cases and proceedings; and (3) challenging the validity of low-quality patents that should not have been issued.

With respect to the Patent Quality Initiative's efforts to challenge the validity of low-quality patents (*i.e.*, patents that should not have been issued because they fail to meet patentability requirements), particular focus will be directed to areas of technology relating to the financial services industry, and shall be implemented, conducted and managed by and in the sole discretion of the Patent Challenge Committee as set forth in the Company's Limited Liability Agreement, as it may be amended from time to time. The Company may publicize the efforts of the Patent Challenge Committee and the resulting invalidation of patents through general news outlets, appropriate business and legal publications, and other means to inform the relevant business and legal communities about those activities.

In undertaking the Purpose (as defined in the Company's Limited Liability Agreement), the Patent Challenge Committee shall be guided by the principles set forth in these Patent Challenge Guidelines.

II. Patent Challenge Guidelines

A. General Guidelines for Patent Challenges

- When considering whether to file a petition for IPR or PGR, the Patent Challenge Committee may consider the following factors in addition to any other facts or circumstances that it believes are important or relevant:
    - the identity and nature of the business of the patent owner;
    - the litigiousness of the patent owner;
    - whether the patent owner historically asserts low quality patents and/or seeks settlements for less than the cost of litigation;
    - whether the patent owner is engaged in, or threatening to engage in, patent litigation with the financial services industry, or is a Person that may have an interest in targeting the financial services industry with patent suits in the near future;
    - the use of the patent by the patent owner, including whether or not the patent owner is engaged in commercialization of the inventions covered by its patents;

- the degree to which claims of the patent could be alleged to cover products or services used throughout the financial services industry;
- the legal quality of the patents, as determined by evaluating claim breadth and prosecution history;
- whether, in the opinion of counsel, there is a very strong likelihood of success of the asserted grounds of invalidity;
- whether the patent has been issued within the past ten years, which will increase the likelihood that there will be a broad array of prior art;
- affiliation of inventors and assignees;
- number and breadth of claims;
- prosecution/litigation history;
- cases, transactions, and licensing of similar portfolios;
- assignment history;
- post-grant proceeding history; and
- whether there are new issues of invalidity for the PTAB to consider that were not substantively addressed on the record by the examiner.

- The Patent Challenge Committee shall have sole discretion to determine how to apply the foregoing criteria and shall not be obligated to take into account any factor in any case.

- The goal of the Patent Challenge Committee should be to file a number of petitions each year consistent with the annual budget and annual target range for patent challenges established by the Executive Committee.

B. Consideration of Activities of the Sole Member and members of the financial services industry

- The Patent Challenge Committee should avoid, if prudent under the circumstances, initiating PTAB proceedings against patents that are the subject of pending or imminent litigation against the Sole Member or members of the financial services industry.
    - With respect to the foregoing, the Patent Challenge Committee should consider whether:

- the patent in question is already (or imminently will be) the subject of pending patent litigation involving the Sole Member or any other Person that is affiliated with or otherwise related to the Sole Member;

- with respect to such patent, a court has already entered a final judgment of infringement and validity against the Sole Member or any other Person that is affiliated with or otherwise related to the Sole Member;

- The Patent Challenge Committee should avoid, if prudent under the circumstances, initiating PTAB proceedings against a patent where initiating the PTAB proceeding would tend to support a finding that the Company is a proxy for the Sole Member.

- The Patent Challenge Committee should not use the same counsel or experts in an IPR or PGR initiated against a Person as the Sole Member or any other Person that is affiliated with or otherwise related to the Sole Member involved in a patent litigation against the same Person.

C. Financial Services Technology.

- The Patent Challenge Committee should initiate PTAB proceedings against patents disclosing alleged inventions that fall within the umbrella of "financial services" technology, and preferably those patents that could be argued to relate to technology used throughout the industry.

D. Experts and Counsel.

- Prior to filing a petition, the Patent Challenge Committee should consider engaging the services of one or more qualified experts in the technology at issue to prepare a declaration and other material supporting the petition. The Patent Challenge Committee should also consider commissioning a prior art search to help determine the strength of a proposed ground of invalidity. In connection with each proposed challenge of the validity of a patent, the Patent Challenge Committee should engage, as it deems appropriate, confer with and rely on the advice of patent counsel about the patent, the prior art, the validity of the patent and the likelihood of success on the merits in the IPR or PGR in the PTAB.

- In connection with carrying out the prosecution of any IPR or PGR proceeding, the Patent Challenge Committee should engage, as it deems appropriate, confer with and rely on the advice of patent counsel.

E. Settlement Strategy.

- In considering whether to settle any proceedings before the PTAB, the Patent Challenge Committee should consider (i) whether the patent owner offers to surrender its patent or agrees to an adverse judgment on all grounds and (ii) whether the settlement is consistent with the funds available to the Patent Challenge Committee.

Certificate Of Completion

Envelope Id: 07968481AA8848A0889622F5618C954B
Status: Completed
Subject: CW2299399 - 2020 PCC Engagement Letter - Glenn Perry - WM.pdf
Source Envelope:
Document Pages: 20 Signatures: 4
Certificate Pages: 2 Initials: 0
AutoNav: Enabled
Envelopeld Stamping: Enabled
Time Zone: (UTC-05:00) Eastern Time (US & Canada)

Envelope Originator:
Lucia P. Vlad
115 Business Park Drive
Winston-Salem, NC 27107
Lucia.Vlad@patentqualityinitiative.com
IP Address: 216.109.110.11

Record Tracking

Status: Original
5/20/2020 | 04:55 PM

Holder: Lucia P. Vlad
Lucia.Vlad@patentqualityinitiative.com

Location: DocuSign

Signer Events	Signature	Timestamp
Glenn Perry gjperry@gmail.com Security Level: Email, Account Authentication (None)	DocuSigned by: Glenn Perry 9BA5CDB039874F7... Signature Adoption: Pre-selected Style Using IP Address: 193.36.224.44	Sent: 5/20/2020 | 04:58 PM Viewed: 5/20/2020 | 05:34 PM Signed: 5/20/2020 | 05:35 PM
Electronic Record and Signature Disclosure: Not Offered via DocuSign		
Jim Howard jim.howard@patentqualityinitiative.com Associate General Counsel Security Level: Email, Account Authentication (None)	DocuSigned by: Jim Howard 7D4FA45EC6CB4DE... Signature Adoption: Pre-selected Style Using IP Address: 199.122.115.5	Sent: 5/20/2020 | 05:35 PM Viewed: 5/20/2020 | 05:40 PM Signed: 5/20/2020 | 05:41 PM
Electronic Record and Signature Disclosure: Not Offered via DocuSign		
Sean Reilly sean.reilly@patentqualityinitiative.com GC Security Level: Email, Account Authentication (None)	DocuSigned by: Sean Reilly Signature Adoption: Pre-selected Style Using IP Address: 199.122.115.5	Sent: 5/20/2020 | 05:41 PM Viewed: 5/20/2020 | 05:50 PM Signed: 5/20/2020 | 05:53 PM
Electronic Record and Signature Disclosure: Not Offered via DocuSign		
Rob Hunter rob.hunter@patentqualityinitiative.com Deputy General Counsel Security Level: Email, Account Authentication (None)	DocuSigned by: Rob Hunter 551*787CA0FD4F7... Signature Adoption: Drawn on Device Using IP Address: 71.71.36.245 Signed using mobile	Sent: 5/20/2020 | 05:53 PM Resent: 5/22/2020 | 11:39 AM Viewed: 5/22/2020 | 11:44 AM Signed: 5/22/2020 | 11:45 AM
Electronic Record and Signature Disclosure: Not Offered via DocuSign		

In Person Signer Events	Signature	Timestamp

Editor Delivery Events	Status	Timestamp
Agent Delivery Events	**Status**	**Timestamp**
Intermediary Delivery Events	**Status**	**Timestamp**
Certified Delivery Events	**Status**	**Timestamp**
Carbon Copy Events	**Status**	**Timestamp**
Witness Events	**Signature**	**Timestamp**
Notary Events	**Signature**	**Timestamp**
Envelope Summary Events	**Status**	**Timestamps**
Envelope Sent	Hashed/Encrypted	5/22/2020 | 11:39 AM
Certified Delivered	Security Checked	5/22/2020 | 11:44 AM
Signing Complete	Security Checked	5/22/2020 | 11:45 AM
Completed	Security Checked	5/22/2020 | 11:45 AM
Payment Events	**Status**	**Timestamps**